Top

BMC Medicine

Published in:

Open Access 01-12-2016 | Research article

Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis

Authors: Ankur Gupta-Wright, Jurgens A. Peters, Clare Flach, Stephen D. Lawn

Published in: BMC Medicine | Issue 1/2016

Abstract

Background

Simple immune capture assays that detect mycobacterial lipoarabinomannan (LAM) antigen in urine are promising new tools for the diagnosis of HIV-associated tuberculosis (HIV-TB). In addition, however, recent prospective cohort studies of patients with HIV-TB have demonstrated associations between LAM in the urine and increased mortality risk during TB treatment, indicating an additional utility of urinary LAM as a prognostic marker. We conducted a systematic review and meta-analysis to summarise the evidence concerning the strength of this relationship in adults with HIV-TB in sub-Saharan Africa, thereby quantifying the assay’s prognostic value.

Methods

We searched MEDLINE and Embase databases using comprehensive search terms for ‘HIV’, ‘TB’, ‘LAM’ and ‘sub-Saharan Africa’. Identified studies were reviewed and selected according to predefined criteria.

Results

We identified 10 studies eligible for inclusion in this systematic review, reporting on a total of 1172 HIV-TB cases. Of these, 512 patients (44 %) tested positive for urinary LAM. After a variable duration of follow-up of between 2 and 6 months, overall case fatality rates among HIV-TB cases varied between 7 % and 53 %. Pooled summary estimates generated by random-effects meta-analysis showed a two-fold increased risk of mortality for urinary LAM-positive HIV-TB cases compared to urinary LAM-negative HIV-TB cases (relative risk 2.3, 95 % confidence interval 1.6–3.1). Some heterogeneity was explained by study setting and patient population in sub-group analyses. Five studies also reported multivariable analyses of risk factors for mortality, and pooled summary estimates demonstrated over two-fold increased mortality risk (odds ratio 2.5, 95 % confidence interval 1.4–4.5) among urinary LAM-positive HIV-TB cases, even after adjustment for other risk factors for mortality, including CD4 cell count.

Conclusions

We have demonstrated that detectable LAM in urine is associated with increased risk of mortality during TB treatment, and that this relationship remains after adjusting for other risk factors for mortality. This may simply be due to a positive test for urinary LAM serving as a marker of higher mycobacterial load and greater disease dissemination and severity. Alternatively, LAM antigen may directly compromise host immune responses through its known immunomodulatory effects. Detectable LAM in the urine is an independent risk factor for mortality among patients receiving treatment for HIV-TB. Further research is warranted to elucidate the underlying mechanisms and to determine whether this vulnerable patient population may benefit from adjunctive interventions.

Available only for authorised users

World Health Organization. Global tuberculosis report 2015. Geneva: WHO; 2015.

Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009;9:173–84. doi:10.1016/S1473-3099(09)70043-X.CrossRefPubMed

Elliott AM, Halwiindi B, Hayes RJ, Luo N, Tembo G, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg. 1993;96:1–11.PubMed

Gilks CF, Brindle RJ, Otieno LS, Bhatt SM, Newnham RS, et al. Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi. AIDS. 1990;4:981–5.CrossRefPubMed

World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO; 2014.

Pai M, Palamountain KM. New tuberculosis technologies: challenges for retooling and scale-up. Int J Tuberc Lung Dis. 2012;16:1281–90. doi:10.5588/ijtld.12.0391.CrossRefPubMed

Lin H-H, Langley I, Mwenda R, Doulla B, Egwaga S, et al. A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools. Int J Tuberc Lung Dis. 2011;15:996–1004. doi:10.5588/ijtld.11.0062.CrossRefPubMed

Choudhry V, Saxena RK. Detection of Mycobacterium tuberculosis antigens in urinary proteins of tuberculosis patients. Eur J Clin Microbiol Infect Dis. 2002;21:1–5.CrossRefPubMed

Kashino SS, Pollock N, Napolitano DR, Rodrigues V, Campos-Neto A. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol. 2008;153:56–62. doi:10.1111/j.1365-2249.2008.03672.x.CrossRefPubMedPubMedCentral

10.

Achkar JM, Lawn SD, Moosa M-YS, Wright CA, Kasprowicz VO. Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT for site-specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration. J Infect Dis. 2011;204(Suppl):S1130–41. doi:10.1093/infdis/jir450.CrossRefPubMedPubMedCentral

11.

Minion J, Leung E, Talbot E, Dheda K, Pai M, et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J. 2011;38:1398–405. doi:10.1183/09031936.00025711.CrossRefPubMed

12.

Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12:201–9. doi:10.1016/S1473-3099(11)70251-1.CrossRefPubMedPubMedCentral

13.

Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012;40:1211–20. doi:10.1183/09031936.00201711.CrossRefPubMed

14.

Fielding KL, Charalambous S, Hoffmann CJ, Johnson S, Tlali M, et al. Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. Trials. 2015;16:125. doi:10.1186/s13063-015-0650-0.CrossRefPubMedPubMedCentral

15.

Peter J. A Trial of the Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients (LAMRCT) NCT01770730. Available: http://clinicaltrials.gov/show/NCT01770730.

16.

Lawn SD. Rapid urine-based Screening for Tuberculosis to reduce AIDS-related Mortality in hospitalized Patients in Africa (STAMP) trial. ISRCTN71603869. Available: http://www.isrctn.com/ISRCTN71603869.

17.

World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy. Geneva: WHO; 2015.

18.

Shah M, Hanrahan CF, Wang Z, Steingart K, Lawn S, et al. Urine lateral flow lipoarabinomannan assay for diagnosing active tuberculosis in adults living with HIV. Cochrane Database Syst Rev. 2014;12:CD011420.

19.

Kerkhoff AD, Wood R, Vogt M, Lawn SD. Prognostic value of a quantitative analysis of lipoarabinomannan in urine from patients with HIV-associated tuberculosis. PLoS One. 2014;9:e103285. doi:10.1371/journal.pone.0103285.CrossRefPubMedPubMedCentral

20.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12. doi:10.1016/j.jclinepi.2009.06.005.CrossRefPubMed

21.

Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36. doi:10.7326/0003-4819-155-8-201110180-00009.CrossRefPubMed

22.

Boehme C, Molokova E, Minja F, Geis S, Loscher T, et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg. 2005;99:893–900. doi:10.1016/j.trstmh.2005.04.014.CrossRefPubMed

23.

Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, et al. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med. 2010;16:262–70. doi:10.1097/MCP.0b013e328337f23a.CrossRefPubMed

24.

Wood R, Racow K, Bekker L-G, Middelkoop K, Vogt M, et al. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect Dis. 2012;12:47. doi:10.1186/1471-2334-12-47.CrossRefPubMedPubMedCentral

25.

Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis. 2012;12:103. doi:10.1186/1471-2334-12-103.CrossRefPubMedPubMedCentral

26.

Cox JA, Lukande RL, Kalungi S, Van Marck E, Van de Vijver K, et al. Is urinary lipoarabinomannan the result of renal tuberculosis? Assessment of the renal histology in an autopsy cohort of Ugandan HIV-infected adults. PLoS One. 2015;10:e0123323. doi:10.1371/journal.pone.0123323.CrossRefPubMedPubMedCentral

27.

Lawn SD, Gupta-Wright A. Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated tuberculosis with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications. Trans R Soc Trop Med Hyg. 2016;110:180–5.CrossRefPubMedPubMedCentral

28.

Manabe YC, Nonyane BA, Nakiyingi L, Mbabazi O, Lubega G, et al. Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda. PLoS One. 2014;9:e101459. doi:10.1371/journal.pone.0101459.CrossRefPubMedPubMedCentral

29.

Nakiyingi L, Ssengooba W, Nakanjako D, Armstrong D, Holshouser M, et al. Predictors and outcomes of mycobacteremia among HIV-infected smear-negative presumptive tuberculosis patients in Uganda. BMC Infect Dis. 2015;15:1–8. doi:10.1186/s12879-015-0812-4.CrossRef

30.

Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr. 2014;66:270–9. doi:10.1097/QAI.0000000000000151.CrossRefPubMedPubMedCentral

31.

Lawn SD, Kerkhoff AD. Rapid diagnosis of TB in HIV-positive in-patients with M. tuberculosis bacteraemia in sub-Saharan Africa. Int J Tuberc Lung Dis. 2015;19:1557–9.CrossRefPubMed

32.

Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker L-G, et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23:1875–80. doi:10.1097/QAD.0b013e32832e05c8.CrossRefPubMed

33.

Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, et al. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol. 2015;10:1077–99. doi:10.2217/fmb.15.9.CrossRefPubMed

34.

Gupta A, Nadkarni G, Yang W-T, Chandrasekhar A, Gupte N, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011;6:e28691. doi:10.1371/journal.pone.0028691.CrossRefPubMedPubMedCentral

35.

Strohmeier GR, Fenton MJ. Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect. 1999;1:709–17. doi:10.1016/S1286-4579(99)80072-0.CrossRefPubMed

36.

Angala SK, Belardinelli JM, Huc-Claustre E, Wheat WH, Jackson M. The cell envelope glycoconjugates of Mycobacterium tuberculosis. Crit Rev Biochem Mol Biol. 2014;49:361–99. doi:10.3109/10409238.2014.925420.CrossRefPubMedPubMedCentral

37.

Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2003;83:91–7.CrossRef

38.

Mishra AK, Driessen NN, Appelmelk BJ, Besra GS. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen interaction. FEMS Microbiol Rev. 2011;35:1126–57. doi:10.1111/j.1574-6976.2011.00276.x.CrossRefPubMedPubMedCentral

39.

Shabaana AK, Kulangara K, Semac I, Parel Y, Ilangumaran S, et al. Mycobacterial lipoarabinomannans modulate cytokine production in human T helper cells by interfering with raft/microdomain signalling. Cell Mol Life Sci. 2005;62:179–87. doi:10.1007/s00018-004-4404-5.CrossRefPubMed

40.

Neyrolles O, Guilhot C. Recent advances in deciphering the contribution of Mycobacterium tuberculosis lipids to pathogenesis. Tuberculosis (Edinb). 2011;91:187–95. doi:10.1016/j.tube.2011.01.002.CrossRef

41.

Joe M, Sun D, Taha H, Completo GC, Croudace JE, et al. The 5-deoxy-5-methylthio-xylofuranose residue in mycobacterial lipoarabinomannan. absolute stereochemistry, linkage position, conformation, and immunomodulatory activity. J Am Chem Soc. 2006;128:5059–72. doi:10.1021/ja057373q.CrossRefPubMed

42.

Garg A, Barnes PF, Roy S, Quiroga MF, Wu S, et al. Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human Mycobacterium tuberculosis infection. Eur J Immunol. 2008;38:459–69.CrossRefPubMedPubMedCentral

43.

Geijtenbeek TBH, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CMJE, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med. 2003;197:7–17.CrossRefPubMedPubMedCentral

44.

Fratti RA, Chua J, Vergne I, Deretic V. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc Natl Acad Sci U S A. 2003;100:5437–42. doi:10.1073/pnas.0737613100.CrossRefPubMedPubMedCentral

45.

Fukuda T, Matsumura T, Ato M, Hamasaki M, Nishiuchi Y, et al. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of mycobacteria and pathogenesis of tuberculosis. MBio. 2013;4:e00472–12. doi:10.1128/mBio.00472-12.CrossRefPubMedPubMedCentral

46.

Briken V, Porcelli SA, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol. 2004;53:391–403. doi:10.1111/j.1365-2958.2004.04183.x.CrossRefPubMed

47.

Shah M, Variava E, Holmes CB, Coppin A, Golub JE, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr. 2009;52:145–51. doi:10.1097/QAI.0b013e3181b98430.CrossRefPubMedPubMedCentral

48.

Lawn SD, Kerkhoff AD, Vogt M, Wood R. Clinical significance of lipoarabinomannan (LAM) detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS. 2012;26:1635–43. doi:10.1097/QAD.0b013e3283553685.CrossRefPubMed

49.

Talbot E, Munseri P, Teixeira P, Matee M, Bakari M, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One. 2012;7:e32876. doi:10.1371/journal.pone.0032876.CrossRefPubMedPubMedCentral

50.

Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons? PLoS One. 2013;8:e54875. doi:10.1371/journal.pone.0054875.CrossRefPubMedPubMedCentral

51.

Balcha TT, Winqvist N, Sturegård E, Skogmar S, Reepalu A, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Trop Med Int Health. 2014;19:734–42. doi:10.1111/tmi.12308.CrossRefPubMed

52.

Drain PK, Gounder L, Grobler A, Sahid F, Bassett IV, et al. Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region: a prospective cohort study. BMJ Open. 2015;5:e006833. doi:10.1136/bmjopen-2014-006833.CrossRefPubMedPubMedCentral

53.

Peter J, Theron G, Chanda D, Clowes P, Rachow A, et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing. BMC Infect Dis. 2015;15:262. doi:10.1186/s12879-015-0967-z.CrossRefPubMedPubMedCentral

54.

Lawn SD, Kerkhoff AD, Burton R, Vogt M, Pahlana P, et al. Systematic investigation for tuberculosis in HIV-infected patients on the first day of admission to a South African hospital: incremental diagnostic yield, accuracy and prognostic value of a urine LAM lateral-flow assay. 45th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union). Barcelona, Spain. 2014. HIV Late Breaker Oral Presentation (HIV_LB04).

55.

Bjerrum S, Kenu E, Lartey M, Newman MJ, Addo KK, et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana–findings from the DETECT HIV-TB study. BMC Infect Dis. 2015;15:407. doi:10.1186/s12879-015-1151-1.CrossRefPubMedPubMedCentral

56.

Cummings MJ, O’Donnell MR. Inverting the pyramid: increasing awareness of mycobacterial sepsis in sub-Saharan Africa. Int J Tuberc Lung Dis. 2015;19:1128–34.CrossRefPubMed

Title: Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis
Authors: Ankur Gupta-Wright
Jurgens A. Peters
Clare Flach
Stephen D. Lawn
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2016
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-016-0603-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration

Evaluation in alcohol use disorders – insights from the nalmefene experience

The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality

Taking advantage of unexpected WebCONSORT results

How important is gametocyte clearance after malaria therapy?